400
Participants
Start Date
January 18, 2019
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2024
Rivaroxaban
new oral anticoagulant molecules which is the selective factor Xa inhibitor
RECRUITING
Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou
Collaborators (1)
Bayer
INDUSTRY
Taizhou Hospital
OTHER
Zhuji People's hospital
UNKNOWN
Shaoxing People's Hospital
OTHER
Jinhua Central Hospital
OTHER
HaiyanPeople's hospital
UNKNOWN
Wenzhou Central Hospital
OTHER
The Central Hospital of Lishui City
OTHER
Dongyang People's Hospital
OTHER
The Third Affiliated Hospital of Wenzhou Medical University
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER